Alpha Teknova, Inc.

Alpha Teknova, Inc. – Fiscal Year 2025 Annual Report Overview

Alpha Teknova, Inc. faces a critical juncture, as revealed in its latest annual report for the fiscal year ended December 31, 2025. This summary distills key financial performance, operational highlights, and significant risks, offering clear, actionable insights for retail investors.

1. Business Overview Alpha Teknova, Inc. specializes in providing critical reagents and media for the life sciences industry. It supports research, development, and manufacturing in areas such as cell therapy, gene therapy, and biopharmaceutical production.

The company operates as a "non-accelerated filer," a "smaller reporting company," and an "emerging growth company." This classification means it is a smaller, growing enterprise with fewer public reporting requirements than larger, established firms. While this offers some operational flexibility, it also implies less extensive public disclosure and potentially less mature internal controls.

As of February 27, 2026, Alpha Teknova had approximately 53.6 million shares of common stock outstanding. The market value of its common stock held by non-affiliates totaled approximately $53.5 million as of June 30, 2025.

2. Competitive Position Alpha Teknova operates within a highly competitive segment of the life sciences tools market. It faces competition from both larger, established companies with extensive resources and smaller, innovative startups.

The company's competitive strategy centers on its specialized expertise. It develops and manufactures critical reagents and media, emphasizing product quality, reliability, and customization. These are crucial for demanding applications in biopharmaceutical research and production, especially within the cell and gene therapy sectors. While acknowledging pressure on pricing and market share, Alpha Teknova aims to differentiate itself through strong customer relationships, technical support, and a responsive approach to evolving industry needs.

3. Financial Performance The company's financial health presents significant challenges. For the fiscal year ended December 31, 2025, Alpha Teknova reported revenue of $45 million, a decline from the prior year, and a net loss of $30 million. These results pushed its cumulative deficit past $150 million, underscoring a history of sustained operating losses.

4. Financial Health The report includes a critical disclosure: management's explicit statement regarding the company's "ability to continue as a going concern." This means management has substantial doubt about the company's capacity to meet its financial obligations and continue operations for the foreseeable future without securing additional funding or achieving profitability.

As of December 31, 2025, the company held $15 million in cash and cash equivalents and reported negative operating cash flow of $25 million for the year. This highlights its urgent need for capital. The company also entered into a Second Amended and Restated Credit Agreement in March 2025, providing access to an additional $10 million in debt financing, which increased its overall debt burden.

5. Management Discussion and Analysis (MD&A) Highlights Management's discussion highlights the significant financial challenges Alpha Teknova faced in fiscal year 2025, primarily driven by declining revenue and persistent operating losses. Challenging market conditions, including reduced customer spending in the biotech sector, and increased operational costs drove these results.

In response, the company implemented a workforce reduction in January 2024 to optimize operational efficiency and reduce its cash burn rate. The subsequent credit agreement restructuring in March 2025 served as a critical step to enhance liquidity, extend debt maturities, and provide additional working capital, though it also increased the company's debt burden. Management emphasizes that the company's ability to continue as a going concern depends on securing additional capital and achieving sustainable profitability.

6. Risk Factors Investors should be aware of several material risks that could impact Alpha Teknova's future performance and stock value:

• Financial Viability & Funding: Ongoing operating losses and negative cash flow necessitate securing significant additional capital. Failure to do so could lead to severe liquidity issues, asset sales, or even bankruptcy.
• Market Demand & Economic Sensitivity: Demand for their specialized reagents and media highly depends on R&D spending within the biotech and pharmaceutical sectors. Economic downturns, inflation, or rising interest rates could reduce customer budgets and increase operational costs, impacting sales and profitability.
• Intense Competition: The life sciences tools market is highly competitive, with established players and innovative startups. Alpha Teknova faces pressure on pricing, product differentiation, and market share from companies with potentially greater resources and broader product portfolios.
• Supply Chain Vulnerabilities: Reliance on specific raw materials, some from single-source suppliers, exposes the company to risks of disruption, quality issues, or price volatility, which could hinder production and increase costs.
• Product Development & Quality Control: The company's growth strategy relies on successful new product development and maintaining stringent quality standards for its critical reagents. Product defects or failures to meet regulatory requirements could lead to costly recalls, reputational damage, and loss of customer trust.
• Regulatory & Intellectual Property Risks: Operating in the life sciences industry involves complex regulatory compliance. Additionally, protecting proprietary technologies and avoiding infringement on others' intellectual property are crucial for long-term success.
• Key Personnel Retention: The loss of critical scientific, technical, or management personnel could significantly disrupt operations, R&D efforts, and strategic execution.
• Manufacturing Expansion Costs: While investing in expanded manufacturing capacity aims for future growth, it represents a substantial capital expenditure that adds to the company's short-term financial burden.

7. Future Outlook and Strategy Alpha Teknova's forward-looking strategy centers on achieving sustainable profitability and strengthening its financial foundation. Key strategic initiatives include continued investment in research and development to expand its product portfolio, particularly in high-growth areas of bioprocessing and advanced therapies. The company also plans to enhance operational efficiencies and optimize its manufacturing processes to improve gross margins and reduce operating expenses. Management acknowledges that securing additional capital through equity financing, further debt, or strategic partnerships remains a critical priority to fund ongoing operations and execute its growth plans.

Conclusion Alpha Teknova, Inc. is navigating a challenging period marked by persistent operating losses, a "going concern" warning, and significant financial and operational risks. While recent actions like workforce reductions and credit restructuring aim to stabilize the company, investors should carefully weigh these factors against its potential in the specialized life sciences market. The company's ability to achieve profitability and secure long-term funding remains paramount.